Annovis Bio, Inc. 

PA

  SEC # 1477845

        

Click to view...

Registrant

About

Filings

Files

Relationships

Names

Topics

Web

Registrant
 SEC-Registered:  12/2/09   —   First EDGAR Filing:  1/15/10   –   Last Filing:  4/26/24 

Business Address      On:  4/26/24       [ Map ]		Mailing Address      On:  4/26/24       [ Map ]
101 Lindenwood Drive, Suite 225 Malvern, Pennsylvania  19355 U.S.A.

Phone #		Organized In		Fiscal-Year End		IRS #		SEC CIK		SEC File #
+1 484-875-3192		Delaware, U.S.A.		12/31/yy		26-2540421		0001477845		001-39202

Market: Symbol:  NYSE: ANVS

— Common Stock

In Major Indexes:	Russell Microcap — NYSE Composite

Industry Classification
GICS – Global Industry Classification Standard:        Sector      →    Sub-Industry   Health Care Biotechnology   ICB – Industry Classification Benchmark:               Industry    →       Subsector      Health Care Biotechnology   SIC:     Code      U.S. Industry      Through      Source      Filings-Review Office 2834 Pharmaceutical Preparations 2024 SEC Office of Life Sciences

        

Management
Director   In   OH   Bruck Claudine 2020-2023   CT   Hoffman Michael B 2020-2023   PA   Maccecchini Maria-Luisa 2020-2023   FL   White Mark K. 2020-2023   PA   McCarthy Reid 2021-2023   MA   Whelan, Jr. Robert M. 2020				Officer  Since  Most-Recent Title   In   MA   Hagopian Henry III 2022 Chief Financial Officer 2023   PA   Maccecchini Maria-Luisa 2020 President & CEO 2023   PA   McGroarty Jeffrey Brian 2020 Chief Financial Officer 2022

        

        

        

        

Securities
Market:  Symbol    Description        (Prices) (Type — Name)   NYSE:  ANVS   Common Stock  _________  Symbol source:  SEC  As of:  4/25/24		CUSIP, CINS or PPN       Description ← Symbol   Issuer Issue (Class or re: Filing — Name)      To 2024:   03615A 03615A·10·8     Common — Common Stock ← ANVS 03615A·01·7     Options _________  Classes source:  Form 13F Filings that list Section 13(f) Securities